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Abstract: Human papillomavirus (HPV) infection is implicated as an important risk factor in the development
of head and neck cancers. Many studies focusing on the relationships between HPV infection and cell cycle
proteins immunoexpression in laryngeal lesions have provided contradictory results. The aim of this study was to
evaluate the relationships between HPV DNA presence and p16INK4a, p21waf1/cip1, p53 and cyclin D1 immu-
noexpression in heterogenous HPV-positive and HPV-negative groups of laryngeal cancers and inverted papil-
lomas. The HPV DNA expression was detected using an in situ hybridization method and immunoexpression of
p16INK4a, p21waf1/cip1, p53 and cyclin D1 using immunohistochemistry. The immunoexpression of p21waf1/
/cip1 and p53 proteins was lower in the HPV-positive group compared to the HPV-negative group, although
only the difference of p53 staining was statistically significant. The immunoexpression of p16INK4a and cyclin
D1 was significantly increased in the HPV-positive group compared to the HPV-negative group. The increased
immunoexpression of p16INK4a and cyclin D1, and the lower immunoexpression of p21waf1/cip1 and p53 in
the HPV-positive group compared to the HPV-negative group, supports the hypothesis that HPV may play an
important role in cell cycle dysregulation. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 34–40)
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Introduction
Head and neck squamous cell carcinoma (HNSCC)
is the sixth commonest cancer, with an annual inci-
dence of approximately 400,000 worldwide. Although
the principal risk factors for head and neck cancer
remain tobacco and alcohol abuse, human papillo-
mavirus (HPV) has recently been found to be etio-
logically associated with 15–35% of cases of HNSCC
[1, 2]. Inverted papillomas are relatively rare epithe-
lial tumors which are of considerable interest because
they have a tendency to recur and to malignant trans-
formation. The nature and pathogenesis of inverted
papillomas are debated. Viral infections are one of
the potential etiological factors [3–8]. It is well known
that HPVs are the etiological agents responsible for
a number of pathologies affecting the stratified epi-
thelia of the skin and anogenital and oropharyngeal
sites [9–11].
Multiple molecular studies have reported that
HPV-mediated tumorigenesis is mainly due to the
activities of two viral oncoproteins: E6 and E7. HPV
E6 is able to induce the degradation of p53 by di-
rect binding to the ubiquitin ligase E6AP, inhibi-
ting p53-dependent signaling upon stress stimuli,
and contributing to tumorigenesis [12–14]. p53 is
a well-known cellular tumor suppressor involved in
processes such as cell cycle progression, DNA re-
pair, chromatin remodeling, differentiation, apop-
tosis and senescence. Neutralization of the p53 tu-
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mor suppressor pathways by increased expression
of HPV E6 and E7 oncogenes can cause disturban-
ces in fundamental cell-cycle proteins [13, 14]. The
expression of E6 and E7 alone is insufficient for
cellular transformation [15], but the additional ge-
netic alterations necessary for malignant progres-
sion in the setting of virus-induced genomic insta-
bility are unknown.
The cell cycle is controlled by a family of cyclins,
cyclin dependent kinases (CDK) and their inhibi-
tors (CDKI) through activating and inactivating
phosphorylation events. Attention has been focused
on the expression of G1 cyclins and cyclin depen-
dent kinases, because the major regulatory events
leading to cell proliferation and differentiation oc-
cur within the G1 phase of the cell cycle. Cyclin D1
is a G1 cyclin that regulates the transition from G1
to S phase, reaching maximum levels of expression
and forming functional kinase complexes with CDK4
or CDK6, during the mid-G1 phase. Active CDK/
/cyclin complex could be regulated by binding to
CDK-inhibitors p16INK4a and p21waf1/cip1, and
inhibit cell cycle progression from G1 to S phase [16].
The p16INK4a functions also as a cyclin-dependent
kinase inhibitor by inhibiting the CDK-induced phos-
phorylation of the retinoblastoma protein (pRb) [17,
18]. The phosphorylation of pRb induces the release
of a transcription factor E2F from the bound form
of E2F and pRb. The release of E2F results in G1-S
transition [19]. Similarly as p16 protein, HPV induces
the release of E2F through the binding of E7 to pRb.
The released E2F stimulates the expression of genes
which are involved in G1-S transition [20]. The in-
activation of pRb by HPV E7 causes p16 overexpres-
sion, because p16 is regulated by negative feedback
of pRb [20–23].
Protein p21waf1/cip1 exists in normal cells in com-
plexes with cyclins, CDKs, and proliferating cell nu-
clear antigen. The induction of p21waf1/cip1is asso-
ciated with terminal differentiation, senescence, and
apoptosis in several tissues. Furthermore, p21waf1/
/cip1 acts as a mediator of wild-type p53 protein, sup-
pressing DNA replication under genomic stress [17,
21, 22]. Although p21waf1/cip1 functions as a puta-
tive tumor suppressor, mutations of the waf1/cip1
gene have been detected only rarely in human malig-
nancies [24], but dysregulation of p16INK4A and
p21waf1/cip1 have recently been reported in various
human tumors.
Therefore, the aim of our study was to evaluate
an immunoexpression of p16INK4a, p21waf1/cip1,
p53 and cyclin D1 in HPV DNA positive and HPV
DNA negative groups of squamous cells carcinoma
of the larynx and sinonasal inverted papillomas.
Material and methods
Patients
A total of 23 formalin-fixed, paraffin-embedded tis-
sue specimens of squamous cell carcinoma of the la-
rynx, and ten sinonasal inverted papillomas, were re-
trieved from archival material (Chair of Pathomor-
phology, Medical University of Lodz). The age range
for sinonasal inverted papillomas was 29 to 78 years
(mean 54.19), and for squamous cell carcinomas of
the larynx it was 47 to 82 years (mean 64.54). Paraffin
tissue sections were stained with hematoxylin and
eosin and the histological diagnoses were established
according to WHO classification [25]. All examined
cases of squamous cell carcinoma of the larynx and
sinonasal inverted papillomas showed histological
signs of HPV infections (koilocytosis, binucleated
squamous cells and increased mitotic activity).
In situ hybridization
The ten sinonasal inverted papillomas and 23 squa-
mous cell carcinomas of the larynx were analyzed us-
ing commercially available HPV DNA probes (Dako,
Carpinteria, California, USA). Initially, a wide spec-
trum biotinylated probe for common HPV subtypes
was used, according to the manufacturer’s suggested
protocol. The wide spectrum probe targets the ge-
nomic DNA of HPV types 6, 11, 16, 18, 31, 33, 35, 39,
45, 51 and 52. Further subtyping was carried out in
the same way, using specific probes for HPV low risk
— LR-HPV (HPV 6 and 11) and HPV high risk —
HR-HPV (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 68). Afterwards, a catalyzed signal amplifica-
tion system (prepared according to the instructions
of the manufacturer) was used (GenPoint, CSA Sys-
tem for in situ hybridization; Dako).
Immunohistochemistry
Paraffin-embedded tissue sections were mounted onto
SuperFrost slides, deparaffinized, then treated in a mi-
crowave oven in a solution of TRS (Target Retrieval
Solution, pH 8.0, Dako) for 30 minutes (2 × 6 minutes
360W, 2 × 5 180W, 2 × 4 minutes 90W) and transferred
to distilled water. Endogenous peroxidase activity was
blocked by 0.3% hydrogen peroxide in distilled water
for 30 minutes, and then sections were rinsed with tris-
buffered saline (TBS, Dako, Denmark) and incubated
for 30 minutes with primary mouse monoclonal anti-
body against: p16INK4a (Santa Cruz; clone F-12, dilu-
tion 1:100); p21waf1/cip1 (Dako; clone SX118, dilution
1:50); p53 (Dako; clone DO-7, dilution 1:50); and cy-
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clin D1 (Dako; clone DCS-6, dilution 1:40). Immunore-
active proteins were visualized using EnVision-horse-
radish peroxidase kit (Dako, Carpinteria, California,
USA) according to the instructions of the manufactu-
rer. Visualization was performed by incubating the sec-
tions in a solution of 3,3'-diaminobenzidine (DakoCy-
tomation, Denmark). After washing, the sections were
counter-stained with hematoxylin and coverslipped. For
each antibody, and for each sample, a negative control
was processed. Negative controls were carried out by
incubation in the absence of the primary antibody and
always yielded negative results.
Morphometry
The p16INK4a, p21waf1/cip1, p53 and cyclin D1 im-
munoexpression was assessed by means of an image
analysis system consisting of a PC equipped with
a Pentagram graphical tablet, Indeo Fast card (frame
grabber, true-color, real-time) produced by Indeo
(Taiwan), and a color TV camera (Panasonic, Japan)
coupled with a Carl Zeiss microscope (Germany).
This system was programmed (MultiScan 8.08 soft-
ware, produced by Computer Scanning System, Po-
land) to calculate the number of objects (automatic
function with manual correction).
Statistical methods
Differences between groups were tested using un-
paired Student’s t-test preceded by evaluation of nor-
mality and Levene’s test. The Mann–Whitney U test
was used where appropriate. Results were deemed
statistically significant if p < 0.05.
Results
Of the ten cases of sinonasal inverted papillomas, one
was positive for HPV DNA using the wide spectrum
probe and for HPV DNA subtypes 6 and 11. In addi-
tion, one case was positive for the HPV wide spec-
trum probe and for high risk HPV probe (Figure 1).
Seven out of the 23 cases of squamous cell carcinoma
were positive for HPV. Of the seven positive cases,
five were positive for both HPV DNA probes: wide
spectrum probe and HPV high risk probe (Figure 2).
In addition, positive reactions for HPV DNA using
high risk probe were noted in two examined cases of
squamous cell carcinomas. All cases of squamous cell
carcinomas and inverted papillomas positive for any
HPV DNA probes were deemed to constitute the
HPV-positive group, and all cases negative for HPV
DNA were deemed to constitute the HPV-negative
group. For statistical purposes, the patients were also
divided into a sinonasal inverted papillomas group
(IP) and a laryngeal cancer group (Ca).
The p21waf1/cip1, p53 and cyclin D1 protein im-
munoexpression was exclusively nuclear, whereas
brown staining of cell nuclei and sometimes cytoplasm
was interpreted as positive staining of the p16INK4a
protein. The immunoexpression of examined proteins
was on a similar level in all cases of HPV-positive and
HPV-negative inverted papillomas and carcinomas
(Table 1). The morphometric data of immunoexpres-
sion of p21waf1/cip1, p16INK4a, p53 and cyclin D1
in the HPV-positive and the HPV-negative group are
shown in Table 2. The immunoexpression of p21waf1/
/cip1 and p53 proteins was lower in the HPV-positive
group compared to the HPV-negative group (Figures
3, 4), although only the difference of p53 immuno-
staining was statistically significant (p < 0.03). The
immunoexpression of p16INK4a and cyclin D1 was
significantly increased in the HPV-positive group
compared to the HPV-negative group (p < 0.005 and
p < 0.03, respectively) (Figures 5, 6).
Discussion
HPV infection is an important risk factor in the de-
velopment of head and neck cancers. At the molecu-
lar level, several differences are linked to HPV sta-
tus, but studies focusing on relationships between
HPV infection and the immunoexpression of cell cy-
cle proteins in laryngeal lesions have provided con-
tradictory results.
Dysfunction of the TP53 tumor suppressor gene
seems to be an early event in carcinogenesis and is as-
sociated with disease progression. It is well known that
inactivation of p53 by HPV E6 plays a crucial role in
cervical tumorigenesis [15]. So far, the impairment of
p53 protein function and its impact on cellular prolife-
ration has not been studied precisely in HPV-positive
head and neck lesions. In our study, the immunoex-
pression of p53 was significantly lower in the HPV-
-positive group compared to the HPV-negative group.
Altavilla et al. [26] and Katori et al. [27] also showed
decreased or no p53 immunoexpression in the HPV-
-positive group compared to the HPV-negative group
of inverted papillomas. Our results support the idea of
neutralization of the p53 gene suppressor pathways by
HPV proteins. In contrast to our results, p53 protein
overexpression has been demonstrated in many pre-
neoplastic and neoplastic lesions of the larynx [28–35].
The lower immunoexpression of p21waf1/cip1 in
the HPV-positive group compared to the HPV-nega-
tive group found in our study is similar to that seen in
other studies. For instance, Katori et al. [27] described
a significant decrease of immunoexpression of
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Figure 1. Positive DNA expression for high risk HPVs
probe in sinonasal inverted papillomas. In situ hybridiza-
tion (magnification × 200)
Figure 2. Positive DNA expression for high risk HPVs
probe in squamous cell carcinoma of the larynx. In situ
hybridization (magnification × 200)
Figure 6. Increased immunoexpression of cyclin D1 in HPV-
-positive group. Immunohistochemistry (magnification × 400)
Figure 5. Increased immunoexpression of p16INK4a in HPV-
-positive group. Immunohistochemistry (magnification × 200)
Figure 4. Decreased immunoexpression of p21waf1/cip1 in
HPV-positive group. Immunohistochemistry (magnifica-
tion × 200)
Figure 3. Decreased immunoexpression of p53 in
HPV-positive group. Immunohistochemistry (magnifica-
tion × 200)
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p21waf1/cip1 in the HPV 16/18 positive group com-
pared to the HPV 16/18 negative group of inverted
papillomas.
Moreover, Malanchi et al. [36, 37] clearly de-
monstrated that HPV E6 may strongly down-regu-
late p21waf1/cip1. In contrast to our results, Altavilla
et al. [26] showed stronger p21waf1/cip1 immunoex-
pression in HPV-positive sinonasal inverted papil-
lomas, and Hafkamp et al. [38] demonstrated that
HPV positivity was strongly correlated with p21waf1/
/cip1 overexpression in tonsillar squamous cell car-
cinomas.
Our results indicated that down-regulation of
p21waf1/cip1 and p53 was associated with the HPV-
-positive group of patients. It is well established that
the prominent function of HPV E6 is inactivation
of p53 and pro-apoptotic proteins, which results in
resistance to apoptosis and increased chromosomal
instability [39, 40]. Overexpression of p21waf1/cip1
decreases E6-induced proliferation, indicating that
the observed down-regulation of p21waf1/cip1 in
HPV-positive cells is an important mechanism for
cell cycle dysregulation. Lower immunoexpression
of p21waf1/cip1 and p53 proteins in the HPV-posi-
tive group strongly suggests that HPV expression
could be involved in p53 inactivation. It must be
taken into consideration that all described diver-
gences concerning p21waf1/cip1 and p53 immu-
noexpression may be connected with an indepen-
dent way of p53 inactivation. Possible explanations
for part of these discordant results are differences
in the number of HPV-positive cases, and method-
ological issues. But it is also possible that HPV-in-
duced oncogenesis and TP53 malfunction due to
genetic abnormalities may be independent events
during the tumorigenesis.
Table 2. Summary of the morphometric data of the immunoexpression of p16, p21, p53 and cyclin D1 and results of in situ
hybridization for HPV-positive (+) and HPV-negative (–) groups
Groups HPV HPV HPV p16 p21 p53 Cyclin D1
WSS 6/11 high risk
HPV IP + + – 18.8 ± 11.2 27.4 ± 17.6 23.2 ± 11.4 13.2 ± 8.6
(+) n = 2 + – +
Ca + – +
n = 7 + – +
+ – +
+ – +
+ – +
– – +
– – +
HPV IP – – – 8.8 ± 6.4 35.2 ± 19.4 35.6 ± 14.4 7.8 ± 4.4
(–) n = 8
Ca – – –
n = 16
p < 0.005 = 0.3 (NS) < 0.03 < 0.03
WSP — wide spectrum probe; IP — sinonasal inverted papilloma; Ca — squamous cell carcinoma of the larynx; HPV — papillomavirus; NS —
not significant
Table 1. Morphometric data of immunoexpression of p16, p21, p53 and cyclin D1 in IP and Ca groups
Groups p16 p21 p53 Cyclin D1
IP HPV (+) n = 2 11.6 ± 7.6 34.7 ± 19.9 33.5 ± 16.1 8.9 ± 5.4
n = 10 HPV (–) n = 8
Ca HPV (+) n = 7 16.0 ± 9.8 27.9 ± 17.1 25.3 ± 9.7 12.1 ± 7.6
n = 23 HPV (–) n = 16
p = 0.22 (NS) = 0.32 (NS) = 0.08 (NS) = 0.23 (NS)
Ca — squamous cell carcinoma of the larynx; IP — sinonasal inverted papilloma; HPV — human papillomavirus; NS — not significant
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In our study, the immunoexpression of the
p16INK4a protein and cyclin D1 was significantly
increased in the HPV-positive group compared to
the HPV-negative group of patients. The literature
data suggests that overexpression of p16INK4a and
cyclin D1 is strongly related to the presence of
HPV16/18. According to Malanchi et al. [36, 37],
HPV16 E6 could induce accumulation of p16 and
cellular proliferation. König et al. [41] demonstra-
ted a statistically significant relationship between the
presence of HPV16/18 DNA  and increased immu-
noexpression of p16INK4a in head and neck squa-
mous cell cancers, but the HPV 6/11 presence was
also significantly correlated with p16INK4a immu-
noreactivity. Altavilla et al. [26] showed strong
p16INK4A and cyclin D1 immunoexpression in
HPV-positive sinonasal inverted papillomas, whereas
Lako et al. [42] observed strong immunoexpression
of p16INK4a in 18 out of 21 cases of HPV-positive
laryngeal papillomas. In contrast to our results,
Marsit et al. [43] showed that positive immunohis-
tochemical D1 staining was inversely related to HPV
16 presence in 698 head and neck cancers. Also
Hafkamp et al. [38], looking at tonsillar squamous
cell carcinomas, described a strong correlation bet-
ween HPV presence and down-regulation of cyclin
D1. However, most researchers agree that high p16
immunoexpression might serve as a marker of HPV
infection, and is a more cost-effective alternative to
ISH and PCR.
HPV-positive tumors differ from HPV-negative
tumors in many regards, including histological appear-
ance, differentiation and prognosis. To the best of our
knowledge, data concerning a correlation between the
immunoexpression of cell cycle proteins and clinical
parameters is scarce. It would be interesting to corre-
late our results with clinical parameters which are
unavailable for current study (development of local
recurrences in the papilloma group; staging parame-
ters and survival data in the laryngeal cancer group).
For this reason, further studies are necessary.
To sum up, our results support the hypothesis of
involvement of HPV in the process of dysregulation of
the cell cycle. Multiple discrepancies concerning im-
munoexpression of cell cycle proteins and HPV pre-
sence can indicate that various pathways of multistep
tumorigenesis do exist. Further studies are needed to
better understand the molecular basis of tumorigene-
sis and the role of HPV infection in this process.
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